NATAP：丙型肝炎病毒 - 即将来什么来

StephenW

Subject: NATAP: HCV - Whats Coming


from Jules: Next month in November the big annual liver meeting AASLD will take place, where we will see the latest new data on new HCV therapies. We already know from the European EASL meeting held in April 2012 that interferon-free therapy regimens composed of 2-4 new oral drugs will be developed. There are 6 new HCV drugs in phase 3 now: 3 new once-daily protease inhibitors, a potent first-in-class NS5A inhibitor, a potent first-in-class nucleotide, and the new PegLambda. In addition right behind this in phase 2b & 2a are many new HCV oral drugs including potent protease inhibitors, NS5A inhibitors, non-nucleoside polymerase inhibitors, as well as a newly developed 2nd nucleotide. At EASL we received the first new data reporting 90% to 100% cure rates with interferon-free regimens of 2-4 new oral drugs. But this was data from the initial regimens, much improved regimens will be developed so this year at AASLD we will see early developments of these newer & better regimens to be. But we will see in the future highly optimized regimens which will provide as much as 100% cure rates. For patients who are the most difficult to treat and who have usually failed previous therapies, including patients with cirrhosis, it will be more challenging to find 100% cure regimens, but researchers are intent on accomplishing this & I predict we will be able to do this either with interferon or IFN-free. In fact research results already showed as much as 100% cure rates with QUAD in highly experienced patients with 2 new oral HCV drugs + pegIFN/RBV, so it is doable but I thik we will find better regimens as well for these hardest to treat patients. The new peginterferon called PegLambda is in phase 3, and looked in phase 2 to be more tolerable than the current peginterferons on the market.
Here are links to tables & discussions of these new drugs, including links to all the data presented for each drug.

HCV Update Selected Highlights: key new HCV drugs, timelines & recent news developments

6 New HCV Drugs in Phase 3 Now   

New HCV Drugs: non nucleoside polymerase inhibitors   

下个月的11月周年肝会议AASLD将采取的地方，在这里，我们将看到新的HCV治疗的最新数据。我们已经知道，从欧洲肝病学会召开2012年4月，干扰素治疗方案，将开发2-4个新的口服药物组成。有6个新的丙型肝炎病毒药物目前在第3阶段：3个新的每日一次的蛋白酶抑制剂是一种有效的第一类NS5A抑制剂是一种有效的第一类核苷酸，和新PegLambda的。除了这背后右侧相2b和2a中，有许多新的HCV的口服药物，包括有力的蛋白酶抑制剂，NS5A抑制剂，非核苷聚合酶抑制剂，以及一个新开发的第二核苷酸。在EASL，我们收到的第一个新2-4新的口服药物干扰素治疗方案的报告数据，90％到100％的治愈率。但是，这是从最初的方案中的数据，大大提高方案将陆续开发，使今年在AASLD，我们将看到这些新的和更好的方案是早期发展。但是，我们会看到在未来高度优化的方案，将提供高达100％的治愈率。谁是最难以治疗，已经没有以前的治疗方法，包括肝硬化患者找到100％的治愈方案，这将是更具挑战性，但研究人员是实现这个目标的意图和我预测的病人，我们能够做到这与干扰素IFN-免费。事实上，研究结果已经表明，与QUAD经验丰富的2个新的口服丙型肝炎病毒药物的患者的治愈率高达100％+ pegIFN / RBV，所以它是可行的，但我黏稠，我们会找到更好的方案，以及为这些最难治疗的患者。新的聚乙二醇干扰素PegLambda是在第三阶段，在第2阶段，并期待更容忍比目前市场上的peginterferons。

下面是链接的表讨论这些新的药物，包括介绍每种药物的所有数据。

HCV更新选定的亮点：重点新HCV药物，时间表和近期新闻动态

现在在第三阶段的6个新的HCV药物

HCV药物：非核苷聚合酶抑制剂